# Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine

> **NCT04384367** · PHASE3 · COMPLETED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 2068 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rizatriptan 10 mg + Naproxen 550mg
- **DRUG:** Maxalt 10Mg Tablet
- **DRUG:** Flanax 550mg
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04384367
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-30
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 2068 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04384367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04384367, "Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04384367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*